Clinical development of resveratrol

Resveratrol: Sources, Production and Health Benefits

Volumn , Issue , 2013, Pages 511-531

  Patel, Ketan R ^a   Steward, William P ^a   Gescher, Andreas J ^a   Brown, Karen ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880337170     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (47)

1. Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W., Fong, H. H., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., Moon, R. C. and Pezzuto, J. M., Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997, 275, 218-20.
2. Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., Pistell, P. J., Poosala, S., Becker, K. G., Boss, O., Gwinn, D., Wang, M., Ramaswamy, S., Fishbein, K. W., Spencer, R. G., Lakatta, E. G., Le Couteur, D., Shaw, R. J., Navas, P., Puigserver, P., Ingram, D. K., de Cabo, R. and Sinclair, D. A., Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006, 444, 337-42.
3. Milne, J. C., Lambert, P. D., Schenk, S., Carney, D. P., Smith, J. J., Gagne, D. J., Jin, L.; Boss, O, Perni, R. B., Vu, C. B., Bemis, J. E., Xie, R., Disch, J. S., Ng, P. Y., Nunes, J. J., Lynch, A. V., Yang, H., Galonek, H., Israelian, K., Choy, W., Iffland, A., Lavu, S., Medvedik, O., Sinclair, D. A., Olefsky, J. M., Jirousek, M. R., Elliott, P. J. and Westphal, C. H., Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007, 450, 712-6.
4. Bhat, K. P. L., Kosmeder, J. W., 2nd, and Pezzuto, J.M., Biological effects of resveratrol. Antioxid Redox Signal. 200, 3, 1041-64.
5. Sun, A. Y., Wang, Q., Simonyi, A. and Sun, G. Y., Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol Neurobiol. 2010, 41, 375-83.
6. Wood, J. G., Rogina, B., Lavu, S., Howitz, K., Helfand, S. L., Tatar, M. and Sinclair, D., Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature. 2004, 430, 686-9.
7. Marier, J. F., Vachon, P., Gritsas, A., Zhang, J., Moreau, J. P. and Ducharme, M. P., Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol ExpTher. 2002, 302, 369-73.
8. Kapetanovic, I. M., Muzzio, M., Huang, Z., Thompson, T. N. and McCormick, D. L., Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol. 2010, 68, 593-601.
9. Walle T., Hsieh, F., de Legge, M. H., Oatis, J. E. Jr. and Walle, U. K., High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004, 32, 1377-82.
10. Boocock, D. J., Faust, G. E., Patel, K. R., Schinas, A. M., Brown, V. A., Ducharme, M. P., Booth, T. D., Crowell, J. A., Perloff, M., Gescher, A. J., Steward, W. P. and Brenner, D. E., Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol BiomarkersPrev. 2007, 16, 1246-52.
11. Brown, V. A., Patel, K. R., Viskaduraki, M., Crowell, J. A., Perloff, M., Booth, T. D., Vasilinin, G., Sen, A., Schinas, A. M., Piccirilli, G., Brown, K., Steward, W. P., Gescher, A. J. and Brenner, D. E., Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010, 70, 9003-11.
12. Almeida, L., Vaz-da-Silva, M., Falcao, A., Soares, E., Costa, R., Loureiro, A. I., Fernandes-Lopes, C., Rocha, J. F., Nunes, T., Wright, L. and Soares-da-Silva, P., Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res. 2009, 53 Suppl 1:S7-15.
13. Vitaglione, P., Sforza, S., Galaverna, G., Ghidini, C., Caporaso, N., Vescovi, P. P., Fogliano, V. and Marchelli, R., Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res. 2005, 49, 495-504.
14. Meng, X., Maliakal, P., Lu, H., Lee, M. J. and Yang, C. S., Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem. 2004, 52, 935-42.
15. Vang, O., Ahmad, N., Baile, C. A., Baur, J. A., Brown, K., Csiszar, A., Das, D. K., Delmas, D., Gottfried, C., Lin, H. Y., Ma, Q. Y., Mukhopadhyay, P., Nalini, N., Pezzuto, J. M., Richard, T., Shukla, Y., Surh, Y. J., Szekeres, T., Szkudelski, T., Walle, T. and Wu, J. M., What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One. 2011, 6, e19881.
16. Nunes, T., Almeida, L., Rocha, J. F., Falcao, A., Fernandes-Lopes, C., Loureiro, A. I., Wright, L., Vaz-da-Silva, M. and Soares-da-Silva, P., Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. J Clin Pharmacol. 2009, 49, 1477-82.
17. Goldberg, D. M., Yan, J. and Soleas, G. J., Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem. 2003, 36, 79-87.
18. Urpi-Sarda, M., Jauregui, O., Lamuela-Raventos, R. M., Jaeger, W., Miksits, M., Covas, M. I. and Andres-Lacueva, C., Uptake of diet resveratrol into the human low-density lipoprotein. Identification and quantification of resveratrol metabolites by liquid chromatography coupled with tandem mass spectrometry. Anal Chem. 2005, 77, 3149-55.
19. Zamora-Ros, R., Urpi-Sarda, M., Lamuela-Raventos, R. M., Estruch, R., Vazquez-Agell, M., Serrano-Martinez, M., Jaeger, W. and Andres-Lacueva, C., Diagnostic performance of urinary resveratrol metabolites as a biomarker of moderate wine consumption. Clin Chem, 2006, 52, 1373-80.
20. Ortuño, J., Covas, M-I., Farre, M., Pujadas, M., Fito, M., Khymenets, O., Andres-Lacueva, C., Roset, P., Joglar, J., Lamuela-Raventós, R. M. and Torre, R. D. L., Matrix effects on the bioavailability of resveratrol in humans. Food Chemistry. 2010, 120, 1123-30.
21. Vaz-da-Silva, M., Loureiro, A. I., Falcao, A., Nunes, T., Rocha, J. F., Fernandes-Lopes, C., Soares, E., Wright, L., Almeida, L. and Soares-da-Silva, P., Effect of food on the pharmacokinetic profile of trans-resveratrol. International journal of clinicalpharmacology and therapeutics. 2008, 46, 564-70.
22. la Porte, C., Voduc, N., Zhang, G., Seguin, I., Tardiff, D., Singhal, N. and Cameron, D. W., Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet. 2010, 49, 449-54.
23. Patel, K. R., Brown, V. A., Jones, D. J., Britton, R. G., Hemingway, D., Miller, A. S., West, K. P., Booth, T. D., Perloff, M., Crowell, J. A., Brenner, D. E., Steward, W. P., Gescher, A. J. and Brown, K., Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010, 70, 7392-9.
24. Sale, S., Tunstall, R. G., Ruparelia, K. C., Potter, G. A., Steward, W. P., and Gescher, A. J., Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4'-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int J Cancer. 2005, 115, 194-201.
25. Kennedy, D. O., Wightman, E. L., Reay, J. L., Lietz, G., Okello, E. J., Wilde, A. and Haskell, C. F., Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr. 2010, 91, 1590-7.
26. Howells, L. M., Berry, D. P., Elliott, P. J., Jacobson, E. W., Hoffmann, E., Hegarty, B., Brown, K., Steward, W. P. and Gescher, A. J., Phase I Randomized, Double-Blind Pilot Study of Micronized Resveratrol (SRT501) in Patients with Hepatic Metastases-Safety, Pharmaco-kinetics, and Pharmacodynamics. Cancer Prev Res (Phila). 2011, 4, 1419-25.
27. Chow, H. H., Garland, L. L., Hsu, C. H., Vining, D. R., Chew, W. M., Miller, J. A., Perloff, M., Crowell, J. A. and Alberts, D. S., Resveratrol modulates drug-and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila Pa). 2010, 3, 1168-75.
28. Burkon, A. and Somoza, V., Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides-two novel resveratrol metabolites in human plasma. Mol Nutr Food Res. 2008, 52, 549-57.
29. Brasnyo, P., Molnar, G. A., Mohas, M., Marko, L., Laczy, B., Cseh, J., Mikolas, E., Szijarto, I. A., Merei, A., Halmai, R., Meszaros, L. G., Sumegi, B. and Wittmann, I., Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011, 106, 383-9.
30. Ghanim, H., Sia, C. L., Korzeniewski, K., Lohano, T., Abuaysheh, S., Marumganti, A., Chaudhuri, A. and Dandona, P., A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J Clin Endocrinol Metab. 2011, 96, 1409-14.
31. Wong, R. H., Howe, P. R., Buckley, J. D., Coates, A. M., Kunz, I. and Berry, N. M., Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutrition,metabolism, and cardiovascular diseases : NMCD. 2011, 21, 851-6.
32. Seymour, E. M., Singer, A. A., Bennink, M. R., Parikh, R. V., Kirakosyan, A., Kaufman, P. B. and Bolling, S. F., Chronic intake of a phytochemical-enriched diet reduces cardiac fibrosis and diastolic dysfunction caused by prolonged salt-sensitive hypertension. The journals of gerontology Series A, Biological sciences and medicalsciences. 2008, 63, 1034-42.
33. Ma, L., Gao, H. Q., Li, B. Y., Ma, Y. B., You, B. A. and Zhang, F. L., Grape seed proanthocyanidin extracts inhibit vascular cell adhesion molecule expression induced by advanced glycation end products through activation of peroxisome proliferators-activated receptor gamma. J Cardiovasc Pharmacol. 2007, 49, 293-8.
34. Sivaprakasapillai, B., Edirisinghe, I., Randolph, J., Steinberg, F. and Kappagoda, T., Effect of grape seed extract on blood pressure in subjects with the metabolic syndrome. Metabolism: clinical and experimental. 2009, 58, 1743-6.
35. Kar, P., Laight, D., Rooprai, H. K., Shaw, K. M. and Cummings, M., Effects of grape seed extract in Type 2 diabetic subjects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stress and insulin sensitivity. Diabetic medicine : A journal ofthe British Diabetic Association. 2009, 26, 526-31.
36. Calamini, B., Ratia, K., Malkowski, M. G., Cuendet, M., Pezzuto, J. M., Santarsiero, B. D. and Mesecar, A. D., Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem J. 2010, 429, 273-82.
37. Hoshino, J., Park, E. J., Kondratyuk, T. P., Marler, L., Pezzuto, J. M., van Breemen, R. B., Mo, S., Li, Y. and Cushman, M., Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem. 2010, 53, 5033-43.
38. Wang, L. X., Heredia, A., Song, H., Zhang, Z., Yu, B., Davis, C. and Redfield, R., Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity. J Pharm Sci. 2004, 93, 2448-57.
39. Williams, L. D., Burdock, G. A., Edwards, J. A., Beck, M., Bausch, J., Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food ChemToxicol. 2009, 47, 2170-82.
40. Kahn, M. E., Senderowicz, A., Sausville, E. A. and Barrett, K. ., Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol. Clin Cancer Res. 2001, 7, 343-9.
41. Blumenstein, I., Keseru, B., Wolter, F. and Stein, J., The chemopreventive agent resveratrol stimulates cyclic AMP-dependent chloride secretion in vitro. Clin CancerRes. 2005, 11, 5651-6.
42. Yu, C., Shin, Y. G., Kosmeder, J. W., Pezzuto, J. M. and van Breemen, R. B., Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid CommunMass Spectrom. 2003, 17, 307-13.
43. Scott, E. N., Gescher, A. J., Steward, W. P. and Brown, K., Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials. Cancer Prev Res (Phila). 2009, 2, 525-30.
44. Ibrahim, Y. H. and Yee D., Insulin-like growth factor-I and cancer risk. Growth HormIGF Res. 2004, 14, 261-9.
45. Ma, J., Pollak, M. N., Giovannucci, E., Chan, J.M., Tao, Y., Hennekens, C. H. and Stampfer, M. J., Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999, 91, 620-5.
46. Rinaldi, S., Cleveland, R., Norat, T., Biessy, C., Rohrmann, S., Linseisen, J., Boeing, H., Pischon, T., Panico, S., Agnoli, C., Palli, D., Tumino, R., Vineis, P., Peeters, P. H., van Gils, C. H., Bueno-de-Mesquita, B. H., Vrieling, A., Allen, N. E., Roddam, A., Bingham, S., Khaw, K. T., Manjer, J., Borgquist, S., Dumeaux, V., Torhild Gram, I., Lund, E., Trichopoulou, A., Makrygiannis, G., Benetou, V., Molina, E., Donate Suarez, I., Barricarte Gurrea, A., Gonzalez, C. A., Tormo, M. J., Altzibar, J. M., Olsen, A., Tjonneland, A., Gronbaek, H., Overvad, K., Clavel-Chapelon, F., Boutron-Ruault, M. C., Morois, S., Slimani, N., Boffetta, P., Jenab, M., Riboli, E. and Kaaks, R., Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer. 2010, 126, 1702-15.
47. Renehan, A.G., Zwahlen, M., Minder, C., O'Dwyer, S.T., Shalet, S.M. and Egger, M., Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004, 363, 1346-53.